News

NewcelX Ltd. Emerges from Merger, Focusing on Neurodegenerative Treatments

NewcelX Ltd. Emerges from Merger, Focusing on Neurodegenerative Treatments

NewcelX Ltd. Launches Following Merger Completion

The merger between NLS Pharmaceutics Ltd. and Kadimastem Ltd. has successfully concluded, resulting in the rebranding of the combined entity as NewcelX Ltd. This newly formed company is set to trade on the Nasdaq Capital Market under the ticker symbol "NCEL." This merger represents a significant shift in the biotechnology landscape, bringing together pioneering discoveries in cell therapy and drug development.

Key Details of the Merger Announcement

NewcelX Ltd. has transitioned from the former NLS Pharmaceutics Ltd. (NASDAQ: NLSP) and has completed the merger agreement that was initially established on November 4, 2024. Effective as of October 30, 2025, the merger has positioned NewcelX for dynamic growth and innovation in the biopharmaceutical industry as it embarks on a new chapter.

Exchange Ratio and Share Structure

In accordance with the merger agreement, shareholders of Kadimastem received a notable exchange rate of 0.706 shares of NewcelX for each ordinary share owned prior to the merger. This exchange was notably adjusted for a reverse stock split ratio of 1-for-10 instituted by NewcelX, aligning with the merger's execution.

Enhancing Value for Shareholders

Holders of common and preferred shares, as well as warrants from NLS at the time of the merger, have also received contingent value rights tied to future success from some of NewcelX's legacy assets. This strategic approach aims at maximizing shareholder value through future revenue streams, including potential proceeds from clinical developments.

Leadership Insights on the Merger

The completion of this merger has been underscored by comments from the executives. Prof. Michel Revel, Chief Scientific Officer of NewcelX, highlighted the capabilities of the new organization, emphasizing its commitment to harnessing cell therapy and innovative drug discovery to improve patient outcomes, particularly for those battling amyotrophic lateral sclerosis (ALS), diabetes, and other neurodegenerative diseases.

Strategic Focus and Clinical Development Plans

As the newly branded NewcelX, preparations are underway to initiate a Phase 2a clinical trial of AstroRx™ aimed at ALS, alongside advancements in the development of IsletRx™ for Type 1 diabetes treatment. This direction underscores NewcelX's commitment to groundbreaking therapies that could alter the quality of life for individuals with chronic conditions.

Company Leadership and Governance Structure

NewcelX is strategically headquartered in Zurich, Switzerland, under the leadership of Ronen Twito, serving as Executive Chairman and Chief Executive Officer. His team includes renowned scientists and experts from both NLS Pharmaceutics and Kadimastem, including a mix of visionary leaders in biotechnology.

About NewcelX Ltd.

NewcelX Ltd. (NASDAQ: NCEL) operates with an integrated biotechnology platform focusing on developing transformative therapies for neurodegenerative and metabolic diseases. By combining advanced stem cell technology and neuroscience, the company aims to launch scalable and effective treatments specifically targeting conditions such as ALS and Type 1 diabetes.

Frequently Asked Questions

What is NewcelX Ltd.?

NewcelX Ltd. is a biotechnology company formed through the merger of NLS Pharmaceutics Ltd. and Kadimastem Ltd., focusing on innovative therapies for neurodegenerative diseases.

What are the ticker symbols for NewcelX Ltd.?

The company will trade under the ticker symbol "NCEL" on the Nasdaq Capital Market.

What therapies is NewcelX developing?

NewcelX is actively developing treatments for conditions like ALS and Type 1 diabetes, leveraging cutting-edge cell-based therapies and drug discovery.

Who is leading NewcelX Ltd.?

Ronen Twito serves as the Executive Chairman and CEO, leading a team of experts in biotechnology and regenerative medicine.

What can shareholders expect post-merger?

Shareholders can expect potential future value from the new company structure, improved clinical outcomes, and innovative therapy pipelines aimed at chronic illnesses.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Biointron's RushDATA™: Speeding Up Antibody Discovery

Updated Category News Views 207

A New Chapter in Antibody Discovery Well, color me intrigued. Biointron, a name you'd recognize if you've got even a toe in the biotech pond, just threw a serious curveball into the antibody discovery game with RushDATA™—an AI- and machine learning-driven platform that's packing a punch. And it's not just about throwing tech buzzwords around; this thing clocks...

Continue Reading
First Horizon's $25M Bet: New Center Transforms Houston

Updated Category News Views 157

New Markets Tax Credits: A Game Changer First things first, if you're thinking this is some typical charitable write-off, think again. First Horizon Bank (NYSE: FHN) is deep in the mix of something pretty transformative in the world of finance and community support. They're not just throwing money at a problem and hoping it sticks. Nope, we're talking real strategy with a...

Continue Reading
When to Switch Your LLC to S Corp Status: Tips

Updated Category News Views 79

Is Your LLC Ready for the S Corp Leap? Thinking about shifting your LLC to S corporation status? You're not alone—many business owners hit this fork in the road as their enterprise starts rolling in more dough. And if you're scratching your head wondering if this switch makes sense for your venture, listen up because timing and context are everything here. When Should...

Continue Reading
Will Hair Loss Drugs Challenge Transplant Clinics?

Updated Category News Views 73

Emerging Treatments Stir Up Hair Loss Scene You ever get the feeling we're on the brink of something big? That's where we are with hair loss treatments, folks. As of late 2026, new drugs are making waves in clinical trials, but they’re not yet giving hair transplant clinics any sleepless nights. Smile Hair Clinic's co-founders, Dr. Mehmet Erdo?an and Dr. Gökay Bilgin,...

Continue Reading
SPOC Energy's Hiring Push Signals Growth Surge

Updated Category News Views 64

A Growing Workforce for a Growing Demand Here we are, smack dab in a bustling week of business news, and among it, SPOC Energy is ramping up its workforce across Alabama. Now, SPOC isn't any run-of-the-mill operation; this Birmingham-based manufacturer messes around with advanced power conversion systems and motor-control automation—a mouthful, sure, but critical stuff...

Continue Reading
Foreigner to Rock Irvine with Night Ranger in 2027

Updated Category News Views 85

Irvine Set for a Rock Revival Talk about a blast from the past! On March 27, 2027, two titans of the rock world, Foreigner and Night Ranger, are set to ignite Irvine like it's the glory days of arena rock all over again. Hosted at the Great Park Live, this show isn't just a concert—it's a full-scale invasion of rock's golden age right into Southern California's heart....

Continue Reading
Philip Scroggie's Legacy in Global Energy Projects

Updated Category News Views 116

A Lifetime of Energy Industry Excellence When you've been around the block in the energy sector as long as Philip D. Scroggie has, you're bound to pick up a few accolades. Recognized as an Inner Circle Lifetime Member, this guy has etched his name in the annals of global energy project management. Yeah, he's been a heavyweight in the oil, gas, and LNG industries, and he's...

Continue Reading
TruGreen Finds New Growth in Birch Hill Acquisition

Updated Category News Views 204

TruGreen's New Chapter Begins In the world of lawn care, TruGreen is sowing the seeds for a revitalized future, courtesy of its recent acquisition by Birch Hill Equity Partners. Based out of Franklin, Tennessee, this powerhouse in the green arena is set to start a fresh chapter, swapping partners like old gloves after a long, 19-year stint with Clayton, Dubilier & Rice...

Continue Reading
The Melt Expands with Key Texas Franchise Deal

Updated Category News Views 130

Throwing Down the Gauntlet: The Melt Expands If there's one thing I've learned after decades watching these restaurant chains multiply like rabbits it’s this: when a veteran gets involved, you perk up. The Melt has done just that by roping in Syed Ahmad—a name that actually means something in this game—to open eight new locations in the Lone Star State. It isn't...

Continue Reading
ADI Global Faces Investor Investigation Over Major Write-Down

Updated Category News Views 60

Towering Goodwill Falls and Investor Scrutiny Well, let's dig into this mess ADI Global Distribution has found itself in. If you were hanging onto ADIG shares, your portfolio probably took quite the hit when they revealed a nasty $659 million goodwill write-down. Imagine opening up those financials and seeing about 62% of goodwill value wiped out overnight. Suddenly, that...

Continue Reading

Top 5 Most Recently Viewed Articles

Arvinas Reflects on Successful Year, Projecting Future Growth

Updated Category News Views 220

Arvinas' Notable Advances in 2024 Arvinas, Inc. (Nasdaq: ARVN), a pioneering clinical-stage biotechnology company, continues on its ambitious path, showing significant progress in 2024. The company has been steadfast in its mission to develop innovative therapies targeting debilitating diseases through its unique PROTAC platform. Their latest advancements signal a...

Continue Reading
Understanding NB Private Equity Partners and Their Recent Buyback

Updated Category News Views 256

NB Private Equity Partners Publishes Share Buyback Details Today, NB Private Equity Partners, commonly referred to as NBPE, has made significant strides to enhance its shareholders' value through a recent buyback of its Class A shares. This transaction, carried out in accordance with the general authority bestowed upon the company’s management by shareholders, showcases...

Continue Reading
China’s AI Innovations Enhance Global Development Efforts

Updated Category News Views 385

China’s Commitment to AI Development In recent years, China has made significant strides in artificial intelligence (AI) development, showcasing its dedication to fostering technological innovation and bolstering cooperation with nations around the world. One of the central aspects of this commitment was highlighted during a recent inspection tour by Chinese President...

Continue Reading
Exploring Crypto-Bound Stocks: A Guide to Peak Investments

Updated Category News Views 209

Bitcoin and Ethereum Driving Market Momentum Recently, Bitcoin experienced a significant breakout, surpassing its previous all-time high of around $112,000 and hitting new heights above $123,000. Although it has cooled off somewhat, it remains consolidated just above its previous resistance level, which now functions as a key support zone. With Bitcoin's year-to-date...

Continue Reading
Verra Mobility's Plunge: A 45% Stock Drop Shakes Investors

Updated Category News Views 147

Surprise Hit: Verra Mobility Takes a Blow Verra Mobility's situation feels like having a rug yanked out from under one's feet. The company sent its shareholders into a tailspin after disclosing a major hit: losing a contract with Avis, which accounted for more than 10% of its annual revenue. We're talking about a stock that nosedived roughly 45%—it's the kind of...

Continue Reading